VEGFA Status as a Predictive Marker of Therapy Outcome in Metastatic Gastric Cancer Patients Following Ramucirumab-Based Treatment.
VEGFA
anti-angiogenic therapy
metastatic Gastric Cancer
micro-vessels
predictive marker
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
07 Oct 2023
07 Oct 2023
Historique:
received:
06
09
2023
revised:
03
10
2023
accepted:
05
10
2023
medline:
28
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
Metastatic gastric cancer (mGC) often has a poor prognosis and may benefit from a few targeted therapies. Ramucirumab-based anti-angiogenic therapy targeting the VEGFR2 represents a milestone in the second-line treatment of mGC. Several studies on different cancers are focusing on the major VEGFR2 ligand status, meaning VEGFA gene copy number and protein overexpression, as a prognostic marker and predictor of response to anti-angiogenic therapy. Following this insight, our study aims to examine the role of VEGFA status as a predictive biomarker for the outcome of second-line therapy with Ramucirumab and paclitaxel in mGC patients. To this purpose, the copy number of the
Identifiants
pubmed: 37893095
pii: biomedicines11102721
doi: 10.3390/biomedicines11102721
pmc: PMC10603940
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italian Ministry of Public Health
ID : n.12/RC2023
Références
Cell. 2019 Mar 7;176(6):1248-1264
pubmed: 30849371
Clin Cancer Res. 2013 Mar 1;19(5):1281-9
pubmed: 23340303
Nat Rev Cancer. 2008 Aug;8(8):579-91
pubmed: 18596824
Physiol Rev. 2011 Jul;91(3):1071-121
pubmed: 21742796
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer Discov. 2014 Jun;4(6):640-1
pubmed: 24891362
Eur J Cancer. 2020 Mar;127:150-157
pubmed: 32014812
Cochrane Database Syst Rev. 2017 Aug 29;8:CD004064
pubmed: 28850174
J Clin Oncol. 2011 Nov 1;29(31):4168-74
pubmed: 21947821
Cancer. 2011 Nov 1;117(21):4925-38
pubmed: 21495021
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
Lancet. 2020 Aug 29;396(10251):635-648
pubmed: 32861308
Cancers (Basel). 2020 Nov 15;12(11):
pubmed: 33203154
Ann Oncol. 2008 Sep;19(9):1523-9
pubmed: 18441328
J Intern Med. 2013 Feb;273(2):114-27
pubmed: 23216836
Nature. 2017 Jan 12;541(7636):169-175
pubmed: 28052061
J Hepatol. 2017 Nov;67(5):999-1008
pubmed: 28687477
BMC Cancer. 2019 Apr 1;19(1):292
pubmed: 30935424
Pharmaceuticals (Basel). 2022 May 24;15(6):
pubmed: 35745570
J Clin Oncol. 2005 Feb 10;23(5):1011-27
pubmed: 15585754
J Clin Pathol. 2007 Jan;60(1):1-7
pubmed: 16790693
Lancet. 2014 Jan 4;383(9911):31-39
pubmed: 24094768
J Clin Oncol. 2012 Nov 10;30(32):3932-8
pubmed: 22987085
Curr Drug Targets. 2010 Aug;11(8):1000-17
pubmed: 20426765
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
Front Oncol. 2023 Apr 14;13:1187014
pubmed: 37124498
World J Gastrointest Oncol. 2022 Jul 15;14(7):1252-1264
pubmed: 36051096
Angiogenesis. 2014 Jul;17(3):519-27
pubmed: 24114200
Breast J. 2007 Mar-Apr;13(2):122-9
pubmed: 17319852
Cancer Discov. 2014 Jun;4(6):730-43
pubmed: 24687604
Int J Biol Sci. 2022 May 29;18(9):3845-3858
pubmed: 35813484
J Leukoc Biol. 2020 Aug;108(2):633-646
pubmed: 32170872
Dig Dis Sci. 2013 Feb;58(2):397-404
pubmed: 22918687
Br J Cancer. 2016 Oct 11;115(8):974-982
pubmed: 27623234
Nat Rev Cancer. 2013 Dec;13(12):871-82
pubmed: 24263190
J Natl Cancer Inst. 2017 Nov 1;109(11):
pubmed: 29059426
Virchows Arch. 2010 Sep;457(3):299-307
pubmed: 20665045
Mod Pathol. 2011 Oct;24(10):1404-12
pubmed: 21743435